Stage B prostate adenocarcinoma: Flow cytometric nuclear DNA ploidy analysis

B. T. Montgomery, O. Nativ, M. L. Blute, G. M. Farrow, R. P. Myers, H. Zincke, Terry M Therneau, M. M. Lieber

Research output: Contribution to journalArticle

79 Citations (Scopus)

Abstract

Over a 16-year period (1966 to 1981), 349 patients underwent radical retropubic prostatectomy for pathologic stage B adenocarcinoma of the prostate. Nuclear DNA content was measured by flow cytometry on available archival material of 283 patients. Two hundred sixty-one patients (92%) had high-quality histograms. The ploidy distribution was as follows: DNA diploid, 177 (68%); DNA tetraploid, 74 (28%); and DNA aneuploid, 10 (4%). The average follow-up was 9.4 years. At the time of follow-up, 53 patients (20%) within the study group had developed tumor progression: 22 local, 23 systemic, and 8 both. The ploidy distribution of the population that developed tumor progression was 27 DNA diploid (51%), 16 DNA tetraploid (30%), and 10 DNA aneuploid (19%). This ploidy distribution is significantly different from that found for the nonprogression group with stage B disease. Overall, 31% of patients with DNA nondiploid tumors had tumors that progressed compared with 15% of patients with DNA diploid tumors. All (100%) DNA aneuploid tumors progressed. The DNA ploidy distribution of all pathologic stage B prostate cancers differs significantly from that found in more advanced stages (C and D1) previously reported for the same time interval. However, the ploidy distribution of stage B tumors that progressed closely resembles that of the stage C and D1 tumors. These results further support the working hypothesis that nuclear DNA content has marked prognostic significance for patients with adenocarcinoma of the prostate. It seems to us that analysis of ploidy by flow or static cytometry will become an essential tool for treating patients with localized prostate cancer.

Original languageEnglish (US)
Pages (from-to)327-331
Number of pages5
JournalArchives of Surgery
Volume125
Issue number3
StatePublished - 1990

Fingerprint

Ploidies
Prostate
Adenocarcinoma
DNA
Neoplasms
Aneuploidy
Diploidy
Tetraploidy
Prostatic Neoplasms
Prostatectomy
Flow Cytometry
Demography

ASJC Scopus subject areas

  • Surgery

Cite this

Montgomery, B. T., Nativ, O., Blute, M. L., Farrow, G. M., Myers, R. P., Zincke, H., ... Lieber, M. M. (1990). Stage B prostate adenocarcinoma: Flow cytometric nuclear DNA ploidy analysis. Archives of Surgery, 125(3), 327-331.

Stage B prostate adenocarcinoma : Flow cytometric nuclear DNA ploidy analysis. / Montgomery, B. T.; Nativ, O.; Blute, M. L.; Farrow, G. M.; Myers, R. P.; Zincke, H.; Therneau, Terry M; Lieber, M. M.

In: Archives of Surgery, Vol. 125, No. 3, 1990, p. 327-331.

Research output: Contribution to journalArticle

Montgomery, BT, Nativ, O, Blute, ML, Farrow, GM, Myers, RP, Zincke, H, Therneau, TM & Lieber, MM 1990, 'Stage B prostate adenocarcinoma: Flow cytometric nuclear DNA ploidy analysis', Archives of Surgery, vol. 125, no. 3, pp. 327-331.
Montgomery BT, Nativ O, Blute ML, Farrow GM, Myers RP, Zincke H et al. Stage B prostate adenocarcinoma: Flow cytometric nuclear DNA ploidy analysis. Archives of Surgery. 1990;125(3):327-331.
Montgomery, B. T. ; Nativ, O. ; Blute, M. L. ; Farrow, G. M. ; Myers, R. P. ; Zincke, H. ; Therneau, Terry M ; Lieber, M. M. / Stage B prostate adenocarcinoma : Flow cytometric nuclear DNA ploidy analysis. In: Archives of Surgery. 1990 ; Vol. 125, No. 3. pp. 327-331.
@article{b6ed41db04c7456ab4c1e52b096e56a4,
title = "Stage B prostate adenocarcinoma: Flow cytometric nuclear DNA ploidy analysis",
abstract = "Over a 16-year period (1966 to 1981), 349 patients underwent radical retropubic prostatectomy for pathologic stage B adenocarcinoma of the prostate. Nuclear DNA content was measured by flow cytometry on available archival material of 283 patients. Two hundred sixty-one patients (92{\%}) had high-quality histograms. The ploidy distribution was as follows: DNA diploid, 177 (68{\%}); DNA tetraploid, 74 (28{\%}); and DNA aneuploid, 10 (4{\%}). The average follow-up was 9.4 years. At the time of follow-up, 53 patients (20{\%}) within the study group had developed tumor progression: 22 local, 23 systemic, and 8 both. The ploidy distribution of the population that developed tumor progression was 27 DNA diploid (51{\%}), 16 DNA tetraploid (30{\%}), and 10 DNA aneuploid (19{\%}). This ploidy distribution is significantly different from that found for the nonprogression group with stage B disease. Overall, 31{\%} of patients with DNA nondiploid tumors had tumors that progressed compared with 15{\%} of patients with DNA diploid tumors. All (100{\%}) DNA aneuploid tumors progressed. The DNA ploidy distribution of all pathologic stage B prostate cancers differs significantly from that found in more advanced stages (C and D1) previously reported for the same time interval. However, the ploidy distribution of stage B tumors that progressed closely resembles that of the stage C and D1 tumors. These results further support the working hypothesis that nuclear DNA content has marked prognostic significance for patients with adenocarcinoma of the prostate. It seems to us that analysis of ploidy by flow or static cytometry will become an essential tool for treating patients with localized prostate cancer.",
author = "Montgomery, {B. T.} and O. Nativ and Blute, {M. L.} and Farrow, {G. M.} and Myers, {R. P.} and H. Zincke and Therneau, {Terry M} and Lieber, {M. M.}",
year = "1990",
language = "English (US)",
volume = "125",
pages = "327--331",
journal = "JAMA Surgery",
issn = "2168-6254",
publisher = "American Medical Association",
number = "3",

}

TY - JOUR

T1 - Stage B prostate adenocarcinoma

T2 - Flow cytometric nuclear DNA ploidy analysis

AU - Montgomery, B. T.

AU - Nativ, O.

AU - Blute, M. L.

AU - Farrow, G. M.

AU - Myers, R. P.

AU - Zincke, H.

AU - Therneau, Terry M

AU - Lieber, M. M.

PY - 1990

Y1 - 1990

N2 - Over a 16-year period (1966 to 1981), 349 patients underwent radical retropubic prostatectomy for pathologic stage B adenocarcinoma of the prostate. Nuclear DNA content was measured by flow cytometry on available archival material of 283 patients. Two hundred sixty-one patients (92%) had high-quality histograms. The ploidy distribution was as follows: DNA diploid, 177 (68%); DNA tetraploid, 74 (28%); and DNA aneuploid, 10 (4%). The average follow-up was 9.4 years. At the time of follow-up, 53 patients (20%) within the study group had developed tumor progression: 22 local, 23 systemic, and 8 both. The ploidy distribution of the population that developed tumor progression was 27 DNA diploid (51%), 16 DNA tetraploid (30%), and 10 DNA aneuploid (19%). This ploidy distribution is significantly different from that found for the nonprogression group with stage B disease. Overall, 31% of patients with DNA nondiploid tumors had tumors that progressed compared with 15% of patients with DNA diploid tumors. All (100%) DNA aneuploid tumors progressed. The DNA ploidy distribution of all pathologic stage B prostate cancers differs significantly from that found in more advanced stages (C and D1) previously reported for the same time interval. However, the ploidy distribution of stage B tumors that progressed closely resembles that of the stage C and D1 tumors. These results further support the working hypothesis that nuclear DNA content has marked prognostic significance for patients with adenocarcinoma of the prostate. It seems to us that analysis of ploidy by flow or static cytometry will become an essential tool for treating patients with localized prostate cancer.

AB - Over a 16-year period (1966 to 1981), 349 patients underwent radical retropubic prostatectomy for pathologic stage B adenocarcinoma of the prostate. Nuclear DNA content was measured by flow cytometry on available archival material of 283 patients. Two hundred sixty-one patients (92%) had high-quality histograms. The ploidy distribution was as follows: DNA diploid, 177 (68%); DNA tetraploid, 74 (28%); and DNA aneuploid, 10 (4%). The average follow-up was 9.4 years. At the time of follow-up, 53 patients (20%) within the study group had developed tumor progression: 22 local, 23 systemic, and 8 both. The ploidy distribution of the population that developed tumor progression was 27 DNA diploid (51%), 16 DNA tetraploid (30%), and 10 DNA aneuploid (19%). This ploidy distribution is significantly different from that found for the nonprogression group with stage B disease. Overall, 31% of patients with DNA nondiploid tumors had tumors that progressed compared with 15% of patients with DNA diploid tumors. All (100%) DNA aneuploid tumors progressed. The DNA ploidy distribution of all pathologic stage B prostate cancers differs significantly from that found in more advanced stages (C and D1) previously reported for the same time interval. However, the ploidy distribution of stage B tumors that progressed closely resembles that of the stage C and D1 tumors. These results further support the working hypothesis that nuclear DNA content has marked prognostic significance for patients with adenocarcinoma of the prostate. It seems to us that analysis of ploidy by flow or static cytometry will become an essential tool for treating patients with localized prostate cancer.

UR - http://www.scopus.com/inward/record.url?scp=0025174806&partnerID=8YFLogxK

UR - http://www.scopus.com/inward/citedby.url?scp=0025174806&partnerID=8YFLogxK

M3 - Article

C2 - 2306181

AN - SCOPUS:0025174806

VL - 125

SP - 327

EP - 331

JO - JAMA Surgery

JF - JAMA Surgery

SN - 2168-6254

IS - 3

ER -